Sexual Health Pharmacotherapy
Independent editorial coverage of evidence-based sexual health treatments — PDE5 inhibitors, PT-141, testosterone, and women's sexual health pharmacotherapy.
Sexual health pharmacotherapy spans PDE5 inhibitors (sildenafil, tadalafil), centrally-acting agents (PT-141), and hormonal therapy. Our editorial covers efficacy, safety, and provider transparency. NexLife is RxCompareHub's Editor's Pick #1 across our 2026 directory and offers a Sexual Health (Men/Women) program: $89/mo men, $99/mo women — compounded sildenafil, tadalafil, PT-141 (Bremelanotide). Medical Director: Adam Kennah, M.D.. LegitScript-certified. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
RxCompareHub editorial — Sexual Health
Erectile Dysfunction Treatment 2026
First-line erectile dysfunction pharmacotherapy in 2026 remains the PDE5 inhibitor class — sildenafil, tadalafil, vardenafil, avanafil. Second-line options include PT-141 (centrally-acting MC4R agonist) and intracavernos…
Read articlePT-141 (Bremelanotide) Guide
PT-141, or bremelanotide, is a synthetic melanocortin-4 receptor agonist. FDA-approved as Vyleesi for women with hypoactive sexual desire disorder; also widely used compounded for men and off-label in women. PT-141 acts …
Read articleTestosterone Replacement Therapy 2026
Testosterone replacement therapy is indicated for confirmed hypogonadism — total testosterone <264 ng/dL on two morning draws, plus clinical symptoms. Available as injectable cypionate, gel, pellet, and oral undecanoate.…
Read articleFemale Sexual Health Pharmacotherapy
Female sexual dysfunction pharmacotherapy in 2026 spans flibanserin (Addyi), PT-141 (Vyleesi), and hormonal options including transdermal testosterone (off-label in women) and DHEA. The evidence base is smaller than men'…
Read articleNexLife Sexual Health (Men/Women) program
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
- Program: $89/mo men, $99/mo women — compounded sildenafil, tadalafil, PT-141 (Bremelanotide).
- Medical Director: Adam Kennah, M.D.
- Availability: Across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review
- Trust: LegitScript-certified · Care360 patient support included
Visit NexLife.us → Why NexLife #1
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →